Vis enkel innførsel

dc.contributor.authorGansmo, Liv Beathe
dc.contributor.authorBjørnslett, Merete Pauline
dc.contributor.authorHalle, Mari Kyllesø
dc.contributor.authorSalvesen, Helga
dc.contributor.authorRomundstad, Pål Richard
dc.contributor.authorHveem, Kristian
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorDørum, Anne
dc.contributor.authorLønning, Per Eystein
dc.contributor.authorKnappskog, Stian
dc.date.accessioned2018-01-02T14:06:45Z
dc.date.available2018-01-02T14:06:45Z
dc.date.created2017-05-13T12:47:51Z
dc.date.issued2017
dc.identifier.citationBMC Cancer. 2017, 17:97, 1-6.nb_NO
dc.identifier.issn1471-2407
dc.identifier.urihttp://hdl.handle.net/11250/2474105
dc.description.abstractBackground The del1518 (rs3730485) polymorphism is an in/del variant in the MDM2 promoter P1. The variant is in complete linkage disequilibrium with MDM2 SNP309 (rs2279744) and has previously been found associated with an increased risk of colon cancer. In this study we assessed the impact of MDM2 del1518 on risk of ovarian and endometrial cancer. Methods Here, we genotyped del1518 in two large hospital-based series of patients diagnosed with ovarian (n = 1,385) or endometrial (n = 1,404) cancer and performed risk estimations as compared to the genotype distribution among 1,872 healthy female controls. Results In overall analysis we observed no association between del1518 and risk of either ovarian or endometrial cancer. However, stratifying according to SNP309 status, we found the del1518 variant to be associated with a reduced risk of endometrial cancer among individuals carrying the SNP309TT genotype both in the dominant (OR = 0.64; 95% CI = 0.45 – 0.90) and the recessive model (OR = 0.80; 95% CI = 0.65 – 1.00). No such association was observed for ovarian cancer risk. Conclusion We found the MDM2 del1518 del variant to be associated with reduced risk of endometrial cancer among individuals carrying the MDM2 SNP309TT genotype.nb_NO
dc.language.isoengnb_NO
dc.publisherBioMed Centralnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleMDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risknb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber1-6nb_NO
dc.source.volume17:97nb_NO
dc.source.journalBMC Cancernb_NO
dc.identifier.doi10.1186/s12885-017-3094-y
dc.identifier.cristin1470064
dc.relation.projectNorges forskningsråd: 220964nb_NO
dc.description.localcodele at the end of the article © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.nb_NO
cristin.unitcode194,65,20,0
cristin.unitcode194,65,20,15
cristin.unitnameInstitutt for samfunnsmedisin og sykepleie
cristin.unitnameHelseundersøkelsen i Nord-Trøndelag
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal